CTLA4 and hypopituitarism: The major cause of hypopituitarism is hypophysitis, whose incidence increases to 6.4% with the use of anti-PD-1/CTLA-4 antibody combination, compared to 3.2% with anti-CTLA-4 antibodies alone, and 0.4% with anti-PD-1 antibodies [3].